Lars Henrik Fugger

Use of calcium channel blockers and Parkinson's disease

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Björn Pasternak
  • ,
  • Henrik Svanström
  • ,
  • Nete M Nielsen
  • ,
  • Lars Fugger
  • Mads Melbye
  • ,
  • Anders Hviid
Experimental evidence and case-control studies suggest that dihydropyridine calcium channel blockers (DiCCBs) may protect against Parkinson's disease. The authors conducted a historical cohort study in Denmark to investigate the association between DiCCB use and risk of Parkinson's disease (1998-2006). Individual-level data on filled drug prescriptions, diagnostic information, and covariates were linked between nationwide registries. Among DiCCB users, 173 incident cases of Parkinson's disease were detected during 461,984 person-years of follow-up, compared with 5,538 cases during 17,343,641 person-years of follow-up among nonusers. After adjustment for age, sex, year, propensity score, and use of other antihypertensive drugs and statins, DiCCB use was associated with a reduced risk of Parkinson's disease (rate ratio (RR) = 0.71, 95% confidence interval (CI): 0.60, 0.82). This association was not present in patients who had previously used DiCCBs (RR = 1.04, 95% CI: 0.87, 1.24). DiCCB users aged ≥65 years were at lower risk of Parkinson's disease than DiCCB users aged
Original languageEnglish
JournalAmerican Journal of Epidemiology
Pages (from-to)627-35
Number of pages9
Publication statusPublished - 2012

See relations at Aarhus University Citationformats

ID: 45489588